Professional Documents
Culture Documents
PRODUCT NAME:
LABORATORY:
DOCUMENTATIÓN DESCRIPTIÓN
NOT NOT
ADMINISTRATIVE REQUIREMENTS COMPLIES
COMPLIES APPLY
Fantasy, generic, pharmacopeic or chemicals
□ □ □
INN name.
(International Pharmaceuticals form □ □ □
Nomination Name) Dosage by pharmaceuticals form □ □ □
Administration route □ □ □
Therapeutic class Anatomical Therapeutic Chemical (ATC) □ □ □
Distinguished:
Manufacturing Regime Finished product, semifinished product and □ □ □
bulk, or semi‐manufacturing.
Details of Producer Name and address □ □ □
Details of importer or
Name and address □ □ □
distributor
Description of content of package sales □ □ □
Description of content of package clinical □ □ □
Description of content of package medical
Product presentation samples □ □ □
Include items or devices incorporated for
□ □ □
administration
Primary package □ □ □
Physical Description of Secondary package □ □ □
packaging material Include items or devices incorporated for
□ □ □
administration
Health certificate authorization □ □ □
Manufacturing agreement signed between the
applicant and producer Laboratory abroad and □ □ □
duly authenticated
Legalized license □ □ □
GMP □ □ □
Legal document in Authorized importation agreement by a notary
□ □ □
Spanish public
Manufacturing agreement or
packaging agreement or □ □ □
National distribution agreement
Quality control agreement with
pharmaceutical company authorized by health □ □ □
authority
PHARMACEUTICAL PRODUCT TECHNICAL INFORMATION
In Spanish and signed by head coach □ □ □
Clinical monograph
With antecedent pharmacologic updated with
and pharmacological □ □ □
activity data, power and toxicity.
Draft of product label for primary and
Draft of product label □ □ □
secondary packages
Page 1 of 4
CHECK LIST FOR REGISTRATION OF PRODUCT IN CHILE
Supported by relevant scientific information □ □ □
Draft of professional
Declaration of Bioavailability and
information □ □ □
Bioequivalence Studies, where required
Draft Package Insert Supported by relevant scientific information □ □ □
PHARMACEUTICAL QUALITY REQUIREMENTS
Qualitative and quantitative statement of the
□ □ □
active
Qualitative and quantitative statement of the
□ □ □
excipient.
Qualitative and quantitative statement of the
excipients used and removed during the □ □ □
manufacturing process
Qualitative and quantitative composition in
Quali – Quantitative
units of mass or volume of the metric system, □ □ □
composition as
or unit of biological activity.
pharmaceuticals form
DCI of API and excipients or pharmacopeia
□ □ □
name
Presence of colorants, specify class name, or
by chemical name or equivalent in indices have □ □ □
Dyes Permitted and approved in the Country
Justify overdose, when appropriate □ □ □
Description of the function of each
□ □ □
component.
Specification and quality control method □ □ □
Declare supplier and manufacturer (attach
□ □ □
analysis report for a specific lot)
Safety data sheet of the active □ □ □
Origin of primary reference standard,
attached certificate of analysis
API (indicate source, potency, □ □ □
traceability to a primary, assays that
characterize it and storage conditions)
Spectrogram or chromatogram of the active
□ □ □
and the standard
Storage conditions of active ingredient raw
□ □ □
material.
Excipients Specifications and control methods □ □ □
Finished product specifications, including
laboratory parameters and acceptance criteria
to be registered as pharmaceutical form, □ □ □
Product specification signed by the technical director and head of
sheet completed Quality Control Department
Include description of primary and secondary
□ □ □
packaging
Include specifications of the solvent □ □ □
Analytical In Spanish, signed by DT and head of Quality □ □ □
Page 2 of 4
CHECK LIST FOR REGISTRATION OF PRODUCT IN CHILE
methodology control department.
Complete that characterizes the
pharmaceutical form and includes all □ □ □
necessary controls to ensure product quality
Validated Analytical Methods whose active
ingredient is not the analytical methodology
□ □ □
described in Pharmacopoeias officially
recognized in Spanish Language.
Determination of impurity, when appropriate □ □ □
Relevant studies (eg. Pharmacokinetic or
□ □ □
dissolution) for modified release dosage forms
Analytical approach of the solvent include,
□ □ □
where appropriate.
Attach certificate of analysis of a specific batch
□ □ □
of the finished product
Attach spectrogram of the sample and
□ □ □
Finished product standard on the specific lot.
Attach certificate of analysis of the standard,
used in analysis of specific lot, drawn to a □ □ □
primary standard.
Bioequivalence and bioavailability (in products
□ □ □
that require it)
Product development studies: chemical,
□ □ □
pharmaceutical and biological, as appropriate
preclinical studies □ □ □
Selective pharmacological studies in animals □ □ □
Toxicological studies in animals (acute toxicity
Studies tests, chronic and those necessary for a proper
□ □ □
(new product) assessment of the safety and tolerability of a
pharmaceutical product)
Clinical studies Phase I, II and III (you may
submit other studies, only if you have □ □ □
pharmaceutical and therapeutic equivalence)
Pharmacokinetic studies (where applicable) □ □ □
Support of the product composition. □ □ □
Clinical report prepared by external expert. □ □ □
Formula studied declare Batch type (industrial,
semi‐industrial or pilot), describe the primary
□ □ □
container, indicate date of manufacture of
each batch and date of start and end of study
Stability study
Substance Identification of the active
(E.E.)
manufacturer and Control Laboratory □ □ □
performing the Stability study
Stability study, performed for 3 batches., both
□ □ □
real time and accelerated
Page 3 of 4
CHECK LIST FOR REGISTRATION OF PRODUCT IN CHILE
Present design Stability study for at least 24
□ □ □
months.
Results first 6 months of Stability study real
□ □ □
time (25°C ±2°C/60% H.R. ±5% H.R.)
Results first 6 months of Stability study
accelerated time (40°C ±2°C/75% H.R. ±5% □ □ □
H.R.)
Report specifications and analytical
□ □ □
procedures used.
Extemporaneous drugs (studies of
□ □ □
reconstituted preparation).
Firm responsible for the stability study □ □ □
Process flow diagrams, summary of the
Technical information manufacturing process with process controls □ □ □
of the manufacturing performed at each stage of manufacture.
process Lotificación system. □ □ □
Validated manufacturing process, in Spanish. □ □ □
Material specification Specifications include dispensing systems (eg
of primary and syringes, cups measures, spoons, cradles) □ □ □
secondary packaging. included in the secondary container.
The presentation to registration process is
done by mail and only physically delivered the
samples (3 units of product sales for any filing,
Others unless the record includes primary packaging □ □ □
different, corresponding to 3 units per
container) and a CD with the trials Case for
new products
Page 4 of 4